This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceuticalmanufacturers. These data remain inconvenient for drugpricing flat earthers (#DPFE): When rebates and discounts were factored in, brand-name drugprices again declined—or grew slowly—in 2023.
In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drugprices. The new law will also require drugmanufacturers to pay rebates to Medicare if they increase drugprices faster than consumer inflation. 5) monitoring access to biosimilars.
Gaulkin — Enacted in 2022, the Inflation Reduction Act (IRA) amended the Medicare provisions of the Social Security Act to impose several discount requirements on pharmaceuticalmanufacturers.
Vanda Pharmaceuticals, Inc. Under the Medicaid Drug Rebate statute, a pharmaceuticalmanufacturer whose drugprices increase faster than the rate of inflation must pay additional per-unit rebates to the program. Centers for Medicare and Medicaid Servs., 23-1457 (4th Cir.
By Faraz Siddiqui — Last week, a federal court in Ohio denied a preliminary injunction motion by four Chambers of Commerce in their lawsuit against the Medicare DrugPrice Negotiation Program. Standing The Defendants questioned, and the court reviewed, Plaintiffs’ standing.
This expansion continues a flawed policy that threatens innovation and jeopardizes patient access to critical treatments, including drugs vital for cancer treatment and popular new weight loss medications that have transformed the management of obesity and related conditions. Read the full statement here.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content